UMI-77 NEW
| Price | $36 | $80 | $122 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: UMI-77 | CAS No.: 518303-20-3 |
| Purity: 98.03% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | UMI-77 |
| Description | UMI-77 is a selective Mcl-1 inhibitor. UMI-77 binds to the BH3-binding groove of Mcl-1 with a Ki of 490 nM and is selective over other members of the Bcl-2 family. |
| Cell Research | Human pancreatic cancer cell lines AsPC-1, BxPC-3, and Capan-2 are cultured in RPMI-1640 medium, whereas Panc-1 and MiaPaCa are cultured in Dulbeccos' Modified Eagle's Medium (DMEM), all supplemented with 10% FBS. The cell growth inhibition after treatment with increasing concentrations of the compounds is determined by WST-8 assay.(Only for Reference) |
| Kinase Assay | Fluorescence polarization (FP)-based binding assays: Based on the Kd values, the concentrations of the proteins used in the competitive binding experiments are 90 nM for Mcl-1, 40 nM for Bcl-w, 50 nM for Bcl-xL, 60 nM for Bcl-2, and 4 nM for A1/Bfl-1. The fluorescent probes, Flu-BID and FAM-BID are fixed at 2 nM for all assays except for A1/Bfl-1 where FAMBID is used at 1 nM. 5 μL of the tested compound in DMSO and 120 μL of protein/probe complex in the assay buffer (100 mM potassium phosphate, pH 7.5; 100 μg/ml bovine gamma globulin; 0.02% sodium azide) are added to assay plates (Microfluor 2Black), incubated at room temperature for 3 h and the polarization values (mP) are measured at an excitation wavelength at 485 nm and an emission wavelength at 530 nm using the plate reader Synergy H1Hybrid. IC50 values are determined by nonlinear regression fitting of the competition curves. |
| In vitro | METHODS: A panel of five PC cell lines (MiaPaCa-2, AsPC-1, Panc-1, BxPC-3, Capan-2) with different expression of anti-apoptotic and pro-apoptotic proteins were treated with UMI-77 (1, 10, 100 μM) and the cytotoxic effects were evaluated. RESULTS The IC50 values ??of UMI-77 against BxPC-3, Panc-1, MiaPaCa-2, AsPC-1, and Capan-2 cell lines were (3.4, 4.4, 12.5, 16.1, 5.5 μM), respectively. [1] |
| In vivo | METHODS: UMI-77 (60, 80 mg/kg, intravenous injection) was used to observe the growth of body weight tumors in the BxPC-3 xenograft model of SCID mice and perform Western blot and immunohistochemical analysis of tumor tissues. RESULTS Treatment with UMI-77 daily for 5 consecutive days per week for two weeks inhibited tumor growth by 65% ??and 56% on day 19 and day 22, respectively; Western blot of tumor tissue lysates showed slightly increased levels of pro-apoptotic proteins Bax and Bak and significantly reduced survivin. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Corn oil : < 8.33 mg/mL (17.79 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+90% (20% SBE-β-CD in Saline) : < 8.33 mg/mL (17.79 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. DMSO : 83.33 mg/mL (177.93 mM), Sonication is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble) 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 8.6 mg/mL (18.36 mM), Solution. 10% DMSO+90% Saline : < 8.33 mg/mL (17.79 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. Ethanol : 86 mg/mL (183.63 mM), Sonication is recommended. |
| Keywords | UMI-77 | Mcl-1 | Inhibitor | inhibit | Bcl-2 Family |
| Inhibitors Related | Cyanoacetamide | Ascorbyl palmitate | Pendimethalin | Amantadine | Hydralazine hydrochloride | Semaglutide | Estradiol benzoate | Navitoclax | N-Hydroxyphthalimide | Venetoclax | Benzbromarone | Thymoquinone |
| Related Compound Libraries | Cuproptosis Compound Library | Apoptosis Compound Library | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Hematonosis Compound Library | Multi-Target Compound Library | Inhibitor Library | Mitochondria-Targeted Compound Library | PPI Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1980.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-04-20 | |
|
VIP3Y
|
ShenZhen H&D Pharmaceutical Technology Co., LTD
|
2026-03-12 | ||
|
Guangzhou Tosun Pharmaceutical Ltd
|
2025-12-19 | |||
| $1.00 |
VIP7Y
|
Career Henan Chemical Co
|
2020-01-02 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY